Quick Answer
BetterLife Pharma Inc. reported Research And Development Expense of $424.3 thousand for the year ending 2025.
- BetterLife Pharma Inc. showed a decrease of -25.7% in Research And Development Expense from 2024 to 2025.
- This data is from BetterLife Pharma Inc.'s annual report (Form 10-K), filed with the SEC on June 2, 2025.
- XBRL data for this metric is available from 2012 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $35.2 thousand | Q3 2011: $13.3 thousand | Q2 2018: $108.8 thousand | Q3 2018: $86.8 thousand | Q4 2018: $65.0 thousand | Q2 2019: $59.5 thousand.
- Over the full 9 years of available data (2012 to 2025), BetterLife Pharma Inc.'s Research And Development Expense has grown by 631.1%.
- Historical annual values: Fiscal year 2025: $424.3 thousand | Fiscal year 2024: $570.9 thousand | Fiscal year 2023: $2.68 million | Fiscal year 2022: $5.42 million | Fiscal year 2021: $284.7 thousand | Fiscal year 2020: $63.8 thousand | Fiscal year 2019: $430.5 thousand | Fiscal year 2018: $90.8 thousand | Fiscal year 2012: $58.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: